Does tranexamic acid reduce health-related quality of life in rural primary-care patients? A case series
Published
January 18, 2026
Paper ID
PAP-000121
Status
Published
DOI
10.65712/tmj.test000379
Advance Services
Abstract
Background: Practice around tranexamic acid varies widely between centres. Methods: The primary outcome was health-related quality of life, assessed blind to allocation. Results: The adjusted odds ratio was 0.45 (95% CI 0.23 to 0.98). health-related quality of life occurred in 9% of the intervention group versus 27% of controls. Conclusion: Strengths include the sample size and blinded outcome assessment.
Introduction
Earlier studies of tranexamic acid were small or single-centre. Practice around tranexamic acid varies widely between centres. The cost of health-related quality of life to health systems is substantial.
The cost of health-related quality of life to health systems is substantial. health-related quality of life remains a leading cause of avoidable harm among rural primary-care patients.
Earlier studies of tranexamic acid were small or single-centre.
Materials and Methods
Eligible participants were rural primary-care patients. The primary outcome was health-related quality of life, assessed blind to allocation. Missing data were handled with multiple imputation.
The primary outcome was health-related quality of life, assessed blind to allocation. We conducted a case series across 12 centres between 2019 and 2023.
We conducted a case series across 6 centres between 2016 and 2021. Missing data were handled with multiple imputation. Eligible participants were rural primary-care patients.
Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.
Results
Serious adverse events were rare and similar between groups. 2789 participants were included (median age 29 years). health-related quality of life occurred in 10% of the intervention group versus 26% of controls. Effects were consistent across prespecified subgroups.
434 participants were included (median age 71 years). Serious adverse events were rare and similar between groups.
| Group | n | Events | Rate % |
|---|---|---|---|
| Centre A | 236 | 93 | 21.8 |
| Age ≥ 65 | 650 | 88 | 18.7 |
| Age < 65 | 331 | 50 | 26.4 |
| Age ≥ 65 | 788 | 101 | 33.2 |
| Control | 660 | 96 | 21.0 |
Values are n (%) unless stated otherwise.

Shown for rural primary-care patients; error bars are 95% confidence intervals.
The adjusted odds ratio was 0.69 (95% CI 0.27 to 0.66). Serious adverse events were rare and similar between groups. health-related quality of life occurred in 15% of the intervention group versus 22% of controls. 3868 participants were included (median age 44 years).
Discussion
Residual confounding cannot be excluded. Future work should test tranexamic acid in a pragmatic multicentre trial. Implementation will depend on staffing, cost and local protocols.
Implementation will depend on staffing, cost and local protocols. Future work should test tranexamic acid in a pragmatic multicentre trial.
Strengths include the sample size and blinded outcome assessment.
Conclusions
Tranexamic acid is a reasonable option for rural primary-care patients to improve health-related quality of life.
References
1. Moreau V, Patel R, et al. Point-of-care ultrasound and acute kidney injury. JAMA. 2019;349(7):375-1691.
2. Novak E, Mensah E, et al. Prone positioning and ventilator-free days. BMC Med. 2019;331(10):311-1195.
3. Patel A, Nasser U, et al. Frailty screening and emergency department revisits. N Engl J Med. 2016;65(12):663-1130.
4. Rossi C, Nakamura D, et al. Home-based cardiac rehabilitation and length of stay. Pediatrics. 2019;376(4):900-1458.
5. Mueller J, Farouk A, et al. Pharmacist-led medication review and time to diagnosis. BMC Med. 2010;375(8):383-992.
Appendices
The statistical analysis plan is in the online supplement.